Physician profile
Mark A Severtson
NPI 1861499576
$774.62
in general payments reported to CMS, 2019-2025
12 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $14.07 · 2021: $45.43 · 2022: $53.40 · 2023: $67.60 · 2024: $110 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $138.95 | 2025 | Tolak |
| Stryker Corporation | $133.71 | 2019 | |
| Med-El Corporation | $126.18 | 2023-2025 | Mi1250 Synchrony 2 Flexsoft, Bci 602 Kit, Adhear Professional Kit |
| Optinose US, INC. | $110.28 | 2020-2024 | |
| Neurent Medical Limited | $55.61 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Integra Lifesciences Corporation | $45.43 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $41.67 | 2023-2024 | Dupixent |
| Acclarent, INC | $39.00 | 2019 | |
| Alk-Abello, INC | $33.37 | 2019-2022 | |
| Pharming Healthcare, INC. | $21.70 | 2024 | Ruconest |
| Hikma Pharmaceuticals USA | $15.42 | 2024 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Severtson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.